Bloomberg Finance Expert: RSI Overbought, Bollinger Bands Narrowing on 15-Minute Chart

According to the 15-minute chart of B, the stock's price has reached an overbought level, as indicated by the Relative Strength Index (RSI) at 09/29/2025 09:45. The Bollinger Bands, which measure the stock's price fluctuations, have also narrowed at this point, suggesting that the magnitude of the price movements has decreased. This implies that the stock price has risen too rapidly and is now exceeding its fundamental support levels.

Autonomix Medical Inc. (AMIX), a pioneer in developing catheter-based neural sensing technologies for neurological disorders, has seen significant developments in recent weeks. As of September 29, 2025, the stock's price has reached an overbought level, as indicated by the Relative Strength Index (RSI) at 09:45 Autonomix Medical Inc Stock Price, News & Analysis^[1]. The Bollinger Bands, which measure the stock's price fluctuations, have also narrowed, suggesting that the magnitude of the price movements has decreased. This implies that the stock price has risen too rapidly and is now exceeding its fundamental support levels.

Despite the overbought conditions, Autonomix Medical has been making strides in its regulatory and research efforts. On September 29, 2025, the company initiated a crucial Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System, targeting pancreatic cancer pain treatment . This study, conducted at CBSET research institute, represents a significant step toward FDA regulatory approvals.

Additionally, Autonomix Medical's technology and findings from the first phase of its first-in-human proof-of-concept study will be presented at the 2025 CIRSE Annual Congress in Barcelona, Spain . The presentation, scheduled for September 15, 2025, will focus on pain mitigation in pancreatic adenocarcinoma using neurolysis via transvascular RF ablation.

These recent developments highlight the company's commitment to advancing innovative technologies in neurological disease management. However, investors should be cautious due to the overbought conditions of the stock, as indicated by the RSI and Bollinger Bands.